Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 9/20 | 0.59 |
| ▸ | CA2 | P00918 | 9/20 | 0.59 |
| ▸ | ACHE | P22303 | 6/20 | 0.59 |
| ▸ | CA12 | O43570 | 4/20 | 0.57 |
| ▸ | CA9 | Q16790 | 3/20 | 0.57 |
| ▸ | CA7 | P43166 | 2/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8073157 | 0.82 | LMNA (0.51) | CA1CA2ACHECA12CA9 | |
| SCHEMBL5919563 | 0.81 | CA1 (0.76) | CA1CA2ACHECA12CA9 | |
| SCHEMBL8283799 | 0.81 | CA1 (0.56) | CA1CA2ACHECA12CA9 | |
| SCHEMBL652527 | 0.80 | LMNA (0.60) | LMNASMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL13843143 | 0.79 | CA1 (0.68) | CA1CA2ACHECA12CA9 | |
| SCHEMBL16697475 | 0.77 | CA12 (0.37) | CA1CA2ACHECA12CA9 | |
| SCHEMBL16697162 | 0.77 | KMT2A (0.50) | CA1CA2 | |
| SCHEMBL13622695 | 0.77 | CA1 (0.57) | CA1CA2ACHECA12CA9 | |
| SCHEMBL8282978 | 0.77 | CA1 (0.57) | CA1CA2ACHECA12CA9 | |
| SCHEMBL964611 | 0.76 | CA1 (0.57) | CA1CA2ACHECA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3066085-B1 | PROCESS FOR THE SYNTHESIS OF AN INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR | INCYTE HOLDINGS CORP (US) | 2020-05-13 | — | — | EP | claimed |
| EP-3066085-A1 | PROCESS FOR THE SYNTHESIS OF AN INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR | Incyte Holdings Corporation (US) | 2016-09-14 | — | — | EP | claimed |
| US-9321755-B2 | Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor | INCYTE CORPORATION (US) | 2016-04-26 | — | — | US | claimed |
| WO-2015070007-A1 | PROCESS FOR THE SYNTHESIS OF AN INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR | INCYTE CORPORATION (US) | 2015-05-14 | — | — | WO | claimed |
| US-20150133674-A1 | PROCESS FOR THE SYNTHESIS OF AN INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR | INCYTE CORPORATION (US) | 2015-05-14 | — | — | US | claimed |
| EP-3744715-A1 | PROCESS FOR THE SYNTHESIS OF AN INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR | Incyte Holdings Corporation (US) | 2020-12-02 | — | — | EP | disclosed |
| EP-3744715-A1 | PROCESS FOR THE SYNTHESIS OF AN INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR | Incyte Holdings Corporation (US) | 2020-12-02 | — | — | EP | disclosed |
| EP-3066085-B1 | PROCESS FOR THE SYNTHESIS OF AN INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR | INCYTE HOLDINGS CORP (US) | 2020-05-13 | — | — | EP | disclosed |
| EP-3066085-B1 | PROCESS FOR THE SYNTHESIS OF AN INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR | INCYTE HOLDINGS CORP (US) | 2020-05-13 | — | — | EP | disclosed |
| US-10280157-B2 | Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor | INCYTE CORPORATION (US) | 2019-05-07 | — | — | US | disclosed |
| US-10280157-B2 | Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor | INCYTE CORPORATION (US) | 2019-05-07 | — | — | US | disclosed |
| US-20180244663-A1 | PROCESS FOR THE SYNTHESIS OF AN INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR | INCYTE CORPORATION | 2018-08-30 | — | — | US | disclosed |
| US-9321755-B2 | Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor | INCYTE CORPORATION (US) | 2016-04-26 | — | — | US | disclosed |
| US-9321755-B2 | Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor | INCYTE CORPORATION (US) | 2016-04-26 | — | — | US | disclosed |
| US-9321755-B2 | Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor | INCYTE CORPORATION (US) | 2016-04-26 | — | — | US | disclosed |
| WO-2015070007-A1 | PROCESS FOR THE SYNTHESIS OF AN INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR | INCYTE CORPORATION (US) | 2015-05-14 | — | — | WO | disclosed |
| WO-2015070007-A1 | PROCESS FOR THE SYNTHESIS OF AN INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR | INCYTE CORPORATION (US) | 2015-05-14 | — | — | WO | disclosed |
| US-20150133674-A1 | PROCESS FOR THE SYNTHESIS OF AN INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR | INCYTE CORPORATION (US) | 2015-05-14 | — | — | US | disclosed |
| US-20150133674-A1 | PROCESS FOR THE SYNTHESIS OF AN INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR | INCYTE CORPORATION (US) | 2015-05-14 | — | — | US | disclosed |
| US-20150133674-A1 | PROCESS FOR THE SYNTHESIS OF AN INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR | INCYTE CORPORATION (US) | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133674-A1 | PROCESS FOR THE SYNTHESIS OF AN INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR | IDO1, INMT, IDO2 | CA1 2067/4885CA2 1698/4885ACHE 2429/4885 |
| US-20180244663-A1 | PROCESS FOR THE SYNTHESIS OF AN INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR | IDO1, INMT, IDO2 | CA1 2067/4885CA2 1698/4885ACHE 2429/4885 |
| US-10280157-B2 | Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor | IDO1, INMT, IDO2 | CA1 2067/4885CA2 1698/4885ACHE 2429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.